The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EVMN | N/A | N/A | N/A | -0% |
| S&P | +17.71% | +82.14% | +12.73% | +4% |
Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.
No news articles found for Evommune.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.00M | 0.0% |
| Gross Profit | $9.69M | 3027.2% |
| Gross Margin | 96.89% | 0.0% |
| Employees | 45 | 0.0% |
| Net Income | -$12,475.00K | 21.6% |
| EBITDA | -$13,017.00K | 19.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $26.82M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $257.27M | 0.0% |
| Short Term Debt | $504.00K | 0.0% |
No data available for this period.
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9,766.00K | 62.8% |
| Operating Free Cash Flow | -$9,635.00K | 63.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|
| Total Debt | $192.95M | $257.82M | $257.77M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
